SOCS3 and head and neck cancer: We used four commercially-available tissue microarrays obtained from three different companies to evaluate SOCS3 expression by immunohistochemistry in various head and neck cancer cases classified by the TNM system as stage 1 through 4 in size, dysplasia grade I through IV, with and without nodal involvement.